SeaStar Medical Holding Corporation, a medical device company, focuses on providing novel solutions and services to treat hyperinflammation and cytokine storm in critically ill patients. The company is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. It is developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure with and without LVAD; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is based in Denver, Colorado.
Over the last 12 months, insiders at SeaStar Medical Holding Corporation have bought $12,716 and sold $0 worth of SeaStar Medical Holding Corporation stock.
On average, over the past 5 years, insiders at SeaStar Medical Holding Corporation have bought $21,875 and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Chung Kevin (Chief Medical Officer) — $12,716.
The last purchase of 4,250 shares for transaction amount of $8,458 was made by Chung Kevin (Chief Medical Officer) on 2024‑11‑18.
2024-11-18 | Chief Medical Officer | 4,250 0.0842% | $1.99 | $8,458 | +6.53% | |||
2024-09-30 | Chief Medical Officer | 1,000 0.025% | $4.26 | $4,258 | -36.97% | |||
2023-11-22 | director | 100,000 0.5274% | $0.40 | $40,000 | +11.90% | |||
2023-05-30 | Chief Medical Officer | 12,543 0.17% | $0.47 | $5,953 | -1.70% | |||
2022-04-05 | Chief Medical Officer | 3,760 0.1986% | $1.85 | $6,956 | -38.29% |
Chung Kevin | Chief Medical Officer | 13685 0.3066% | $1.98 | 4 | 0 | <0.0001% |
Van Heel Kenneth | director | 116400 2.608% | $1.98 | 1 | 0 |